While important advances have been made in pre-venting hepatitis C, therapy for this disease among favourable factors for a sustained response among an ESRD population with HCV. Duration of disease, ESRD patients remains unsatisfactory. In fact, valid animal models and effective cell culture systems with source of HCV infection, iron status, patient age and HCV quasispecies diversity all play a role in the IFN which to study HCV are lacking.
At present, the most important therapy for hepatitis response among patients with normal renal function, but their influence among ESRD patients with HCV C in ESRD patients is interferon (IFN ), but it is expensive and has limited efficacy and safety. is unclear.
A high side-effects rate of IFN therapy in HD has Alternative approaches based on new formulations of IFN are currently under way and combinations of been observed in some studies. The most important side-effects are flu-like symptoms (which respond IFN with nucleotide analogues (i.e. ribavirin) are giving encouraging results in the treatment of chronic well to the administration of paracetamol ), weight loss, hypoalbuminaemia, anaemia with resistance hepatitis C among patients with normal renal function [2] [3] [4] . These findings may have a clinical impact on to erythropoietin, and depression of leukocytes and thrombocytes. It is possible that the altered pharmacothe therapy for hepatitis C among ESRD patients.
In this report, we briefly summarize the therapeutic kinetic parameters of IFN in chronic uraemia may, to some extent, explain the numerous side-effects found options for the treatment of hepatitis C in ESRD highlighting the most recent and novel advances in by some authors.
IFN has been used to facilitate renal transplantation this field.
in patients on dialysis with chronic HCV who are renal transplant candidates. In some individuals a persistent
Interferon treatment of HCV in ESRD
biochemical response after renal transplantation has been observed; in one patient histological progression did not occur. However, no virological data were The only therapeutic regimen that has been proven to be effective in chronic HCV infection among ESRD available at follow-up [9] .
IFN has also been used in the treatment of HCV patients is IFN (mostly IFN-a). IFN-a exhibits a variety of antiviral, immunomodulatory and antiprolif-after renal transplantation; however, it failed to clear HCV RNA and the tolerance of the drug was poor. A erative activities. The mechanisms through which IFNs operate are only partially understood.
high incidence of renal dysfunction, including renal failure and acute allograft rejection has been observed Numerous reports [5] have been published regarding the IFN treatment of hepatitis C among dialysis in association with IFN use in transplant recipients.
At present, it cannot be recommended for general use patients. They mostly concern uncontrolled trials showing a rate of immediate and sustained biochem-in kidney transplant recipients. ical, histological and virological response similar to patients with normal renal function.
Novel treatments for HCV in ESRD
The only double-blind, controlled trial on IFN therapy of HCV in HD patients is that of Fernandez et al. [6 ] , who observed a short-term biochemical Alternative approaches based on higher doses of IFNa (up to 30 million per week) or a longer duration of response that was significantly higher in the IFN group than among placebo patients. The biochemical and treatment (18-24 months) remain to be explored in ESRD. However, these schedules are likely to be costly. virological response 12 months after therapy was also higher in the IFN group compared with controls;
The efficacy of various types of interferon (i.e. IFNb, IFN-con-1) is still uncertain in ESRD. It is possible however, this difference was not statistically significant.
However, the vast majority of trials concerning IFN that some of them will show high efficacy. IFNalphacon-1, also called consensus IFN, is the first in dialysis are biased by the fact that only patients with biochemical and/or histological evidence of bioengineered IFN. In fact, it is a wholly synthetic type I IFN developed using various portions of other chronic active hepatitis have been selected. These patients show more severe disease and are less likely IFNs resulting in a consensus sequence. More recently, long-acting a-IFNs have been developed by covalent to have a sustained response.
The mechanisms responsible for the relatively high modifications of the IFN molecule using polyethylene glycol (pegylation). The 'pegylated' IFNs can be sustained response to IFN in dialysis patients in spite of the immune compromise conferred from chronic administered weekly and provide more sustained levels of a-IFN. uraemia are unclear. HD patients with HCV have a low viral load, IFN could help to restore the cellIt is worthwhile recognizing that although IFN treatment may be associated with favourable effects mediated immunity depressed by chronic uraemia, an increase of IFN activity during HD sessions has been on biochemical and virological markers, its effects on quality of life and disease progression remain shown recently [7] . In addition, it has recently been discovered that the clearance of IFN-a is about half undetermined.
New classes of drugs, such as HCV NS3 protease that in a dialysis population compared with nonuraemic patients [8] . The response to IFN is also and helicase inhibitors promise to be highly effective in lowering or suppressing viral replication. They are associated with numerous host-and virus-related factors. HCV genotype 1b and mild liver pathology are based on extensive research about the molecular struc-ture of HCV, which indicates several potential means separate evaluation in view of their immunosuppressed state and the risk of hepatic flare after renal transof inhibiting viral replication.
plantation. Effective therapy for hepatitis C in ESRD is an important goal made more important by the poor prospects for an effective vaccine against HCV.
Combination of IFN-a and ribavirin
Most recently, combinations of IFN-a plus ribavirin, an oral nucleoside analogue, have been evaluated. Conclusions
Ribavirin is a synthetic guanosine analogue with activ-An effective and safe therapy for hepatitis C in ESRD ity against a broad spectrum of DNA and RNA is not yet available. Trials with new IFN formulations viruses, and which shows direct antiviral and immuno-are under way, and some of them promise to be highly modulatory effects. It is approved for use in the USA effective. The role of these newer formulations in in aerosol form as therapy for respiratory syncytial the ESRD population remains to be established. virus infection in infants. Treatment with ribavirin Synergistic combination regimens (i.e. IFN plus ribavialone has no effect on serum HCV RNA levels, rin) aimed at maximizing the antiviral activity promise although it does lead to a transient decrease in amino-to be an important advance in the therapy of HCV in transferase levels. Large multicentre, randomized and ESRD. Large prospective, controlled and randomized controlled trials have recently been developed trials are clearly warranted in order to verify the expanding the preliminary experience on the higher efficacy, tolerance and safety of concomitant adminisefficacy of the combination of IFN plus ribavirin tration of IFN and ribavirin for HCV in ESRD. In compared with IFN alone. These trials have indicated the meantime, it is appropriate to evaluate IFN therapy that the simultaneous administration of ribavirin and for patients on dialysis who have HCV and who are IFN represents an important advance in the treatment serious renal transplant candidates. of hepatitis C among patients with normal renal function [2] [3] [4] . The standard schedule currently proposed is the concomitant administration of 1000/1200 mg of ribavirin orally each day plus 3 000 000 IU (3 MU ) of References IFN thrice weekly for 6 months. The rate of sustained relapsers. These rates are several times higher than
